var initContents = [{"A":"レジメン名","B":"[G]適応疾患","C":"表示","D":"[r]レジメン使用上の注意","E":"[S]投与時間","F":"投与スケジュール","G":"その他","H":"[drug1]","I":"[drug2]","J":"[drug3]","K":"[drug4]","L":"[drug5]","M":"[drug6]","N":"[drug7]","O":"[drug8]","P":"[drug9]","Q":"[drug10]","__rowNum__":0},{"A":"ABVD","B":"１）血液","__rowNum__":1},{"A":"RIT単剤","B":"１）血液","__rowNum__":2},{"A":"CHOP","B":"１）血液","__rowNum__":3},{"A":"CHOP (VDS)","B":"１）血液","__rowNum__":4},{"A":"THP-COP","B":"１）血液","__rowNum__":5},{"A":"THP-COP(VDS)","B":"１）血液","__rowNum__":6},{"A":"R-CHOP","B":"１）血液","__rowNum__":7},{"A":"R-CHOP(VDS)","B":"１）血液","__rowNum__":8},{"A":"R-THP-COP","B":"１）血液","__rowNum__":9},{"A":"R-THP-COP(VDS)","B":"１）血液","__rowNum__":10},{"A":"THP-CEP","B":"１）血液","__rowNum__":11},{"A":"CVP","B":"１）血液","__rowNum__":12},{"A":"R-CVP","B":"１）血液","__rowNum__":13},{"A":"Velcade【週２回投与】","B":"１）血液","__rowNum__":14},{"A":"Velcade【週１回投与】","B":"１）血液","__rowNum__":15},{"A":"iPAd療法【Dox：9mg/m2】","B":"１）血液","C":"非表示","__rowNum__":16},{"A":"iPAd療法【Dox：18mg/m2】","B":"１）血液","C":"非表示","__rowNum__":17},{"A":"VAD","B":"１）血液","__rowNum__":18},{"A":"地固め（第１）BH-AC/MIT","B":"１）血液","C":"非表示","__rowNum__":19},{"A":"地固め（第１）BH-AC/MIT【70歳以上】","B":"１）血液","C":"非表示","__rowNum__":20},{"A":"地固め（第２）BH-AC/DNR/ETP","B":"１）血液","C":"非表示","__rowNum__":21},{"A":"地固め（第２）BH-AC/DNR/ETP【70歳以上】","B":"１）血液","C":"非表示","__rowNum__":22},{"A":"地固め（第３）BH-AC/ACR","B":"１）血液","C":"非表示","__rowNum__":23},{"A":"地固め（第３）BH-AC/ACR【70歳以上】","B":"１）血液","C":"非表示","__rowNum__":24},{"A":"MEC","B":"１）血液","__rowNum__":25},{"A":"VEP","B":"１）血液","C":"非表示","__rowNum__":26},{"A":"大量CPA(HD-CY)","B":"１）血液","__rowNum__":27},{"A":"大量L-PAM","B":"１）血液","__rowNum__":28},{"A":"FC併用療法","B":"１）血液","__rowNum__":29},{"A":"PBSCHに伴うCPA大量療法","B":"１）血液","__rowNum__":30},{"A":"FOLFOX4","B":"１）血液","C":"非表示","__rowNum__":31},{"A":"DCEP","B":"１）血液","__rowNum__":32},{"A":"IDEA","B":"１）血液","C":"非表示","__rowNum__":33},{"A":"CP-R","B":"１）血液","C":"非表示","__rowNum__":34},{"A":"ALL202－O（25～59歳）【VCR】","B":"１）血液","__rowNum__":35},{"A":"ALL202－O（25～59歳）【VDS】","B":"１）血液","C":"非表示","__rowNum__":36},{"A":"ALL202－O（60歳以上）【VCR】","B":"１）血液","__rowNum__":37},{"A":"ALL202－O（60歳以上）【VDS】","B":"１）血液","C":"非表示","__rowNum__":38},{"A":"地固め療法C1 （15～59歳）","B":"１）血液","C":"非表示","__rowNum__":39},{"A":"地固め・強化第３コース","B":"１）血液","C":"非表示","__rowNum__":40},{"A":"地固め療法-4(A triple V)","B":"１）血液","__rowNum__":41},{"A":"BEAM","B":"１）血液","C":"非表示","__rowNum__":42},{"A":"MEAM（BEAM変法）","B":"１）血液","__rowNum__":43},{"A":"DeVIC","B":"１）血液","__rowNum__":44},{"A":"EPOCH","B":"１）血液","__rowNum__":45},{"A":"EPOCH-R","B":"１）血液","__rowNum__":46},{"A":"CHASE","B":"１）血液","__rowNum__":47},{"A":"CHASER","B":"１）血液","__rowNum__":48},{"A":"ESHAP","B":"１）血液","__rowNum__":49},{"A":"MOPP","B":"１）血液","C":"非表示","__rowNum__":50},{"A":"DHAP(CDDP：day1のみ）","B":"１）血液","C":"非表示","__rowNum__":51},{"A":"DHAP(1サイクル目）","B":"１）血液","C":"非表示","__rowNum__":52},{"A":"DHAP(2サイクル目）","B":"１）血液","C":"非表示","__rowNum__":53},{"A":"R-DHAP(1サイクル目）","B":"１）血液","C":"非表示","__rowNum__":54},{"A":"R-DHAP(2サイクル目）","B":"１）血液","C":"非表示","__rowNum__":55},{"A":"R-MA","B":"１）血液","__rowNum__":56},{"A":"R-HyperCVAD","B":"１）血液","__rowNum__":57},{"A":"ICE","B":"１）血液","C":"非表示","__rowNum__":58},{"A":"R-ICE","B":"１）血液","C":"非表示","__rowNum__":59},{"A":"FCM","B":"１）血液","C":"非表示","__rowNum__":60},{"A":"R-FCM","B":"１）血液","C":"非表示","__rowNum__":61},{"A":"2-CdA（持続投与）","B":"１）血液","C":"非表示","__rowNum__":62},{"A":"2-CdA（２時間投与）","B":"１）血液","C":"非表示","__rowNum__":63},{"A":"FND","B":"１）血液","__rowNum__":64},{"A":"R-FND","B":"１）血液","C":"非表示","__rowNum__":65},{"A":"ROAD","B":"１）血液","C":"非表示","__rowNum__":66},{"A":"APL97寛解導入療法B","B":"１）血液","C":"非表示","__rowNum__":67},{"A":"APL97寛解導入療法C(Ara-C：5日間）","B":"１）血液","C":"非表示","__rowNum__":68},{"A":"APL97寛解導入療法C(Ara-C：7日間）","B":"１）血液","C":"非表示","__rowNum__":69},{"A":"CA療法","B":"１）血液","__rowNum__":70},{"A":"CAG療法","B":"１）血液","__rowNum__":71},{"A":"LSG15(VCAP療法)","B":"１）血液","__rowNum__":72},{"A":"LSG15(AMP療法)","B":"１）血液","__rowNum__":73},{"A":"LSG15(VECP療法）","B":"１）血液","__rowNum__":74},{"A":"寛解導入療法（DNR/Ara-C)","B":"１）血液","__rowNum__":75},{"A":"寛解導入療法（IDR/Ara-C)","B":"１）血液","__rowNum__":76},{"A":"地固め療法-3(ACR/Ara-C)","B":"１）血液","__rowNum__":77},{"A":"地固め療法 （BHAC/ACR）","B":"１）血液","C":"非表示","__rowNum__":78},{"A":"地固め療法 （BHAC/ETP/DNR/6MP)","B":"１）血液","C":"非表示","__rowNum__":79},{"A":"地固め療法-2(DNR/Ara-C)","B":"１）血液","__rowNum__":80},{"A":"地固め療法 （IDR/Ara-C）","B":"１）血液","C":"非表示","__rowNum__":81},{"A":"地固め療法-1(MIT/Ara-C)","B":"１）血液","__rowNum__":82},{"A":"髄注 （MTX/Ara-C/PSL)","B":"１）血液","__rowNum__":83},{"A":"地固め療法１(EBVP)","B":"１）血液","C":"非表示","__rowNum__":84},{"A":"地固め療法2(MB)","B":"１）血液","C":"非表示","__rowNum__":85},{"A":"地固め療法3(CAVP)","B":"１）血液","C":"非表示","__rowNum__":86},{"A":"地固め療法4(MA)","B":"１）血液","C":"非表示","__rowNum__":87},{"A":"M-BACOD療法","B":"１）血液","C":"非表示","__rowNum__":88},{"A":"m-BACOD療法","B":"１）血液","C":"非表示","__rowNum__":89},{"A":"寛解導入療法A(Set療法）","B":"１）血液","C":"非表示","__rowNum__":90},{"A":"寛解導入療法B(individualized療法）","B":"１）血液","C":"非表示","__rowNum__":91},{"A":"AML201 地固め療法-C群(Ara-C大量療法）","B":"１）血液","__rowNum__":92},{"A":"APL204寛解導入療法B群(ATRA/IDA/Ara-C)","B":"１）血液","C":"非表示","__rowNum__":93},{"A":"APL204寛解導入療法C群(ATRA/IDA/Ara-C)","B":"１）血液","C":"非表示","__rowNum__":94},{"A":"APL204寛解導入療法D-A群(IDA/Ara-C)","B":"１）血液","__rowNum__":95},{"A":"APL204寛解導入療法D-B群(IDA/Ara-C)","B":"１）血液","C":"非表示","__rowNum__":96},{"A":"APL204寛解導入療法D-C群(IDA)","B":"１）血液","C":"非表示","__rowNum__":97},{"A":"MTX大量投与＋α","B":"１）血液","__rowNum__":98},{"A":"VeMP療法","B":"１）血液","C":"非表示","__rowNum__":99},{"A":"ALL202－O C1(HdAC phase)","B":"１）血液","__rowNum__":100},{"A":"Aza【点滴静注】","B":"１）血液","__rowNum__":101},{"A":"ALL202－O C2：MTX phase-B","B":"１）血液","C":"非表示","__rowNum__":102},{"A":"JPLSG HLH2004","B":"１）血液","C":"非表示","__rowNum__":103},{"A":"ALL202－O C3：reinduction【VCR】","B":"１）血液","__rowNum__":104},{"A":"ALL202－O C3：reinduction【VDS】","B":"１）血液","C":"非表示","__rowNum__":105},{"A":"LEED","B":"１）血液","__rowNum__":106},{"A":"Bendamustine療法","B":"１）血液","__rowNum__":107},{"A":"R-Bendamustine療法【３日間】","B":"１）血液","__rowNum__":108},{"A":"CyBorD","B":"１）血液","C":"非表示","__rowNum__":109},{"A":"GO療法","B":"１）血液","C":"非表示","__rowNum__":110},{"A":"ALL202","B":"１）血液","__rowNum__":111},{"A":"SMILE療法","B":"１）血液","C":"非表示","__rowNum__":112},{"A":"sVCD療法","B":"１）血液","C":"非表示","__rowNum__":113},{"A":"L-PAM大量＋Bor","B":"１）血液","C":"非表示","__rowNum__":114},{"A":"抗CCR抗体療法","B":"１）血液","__rowNum__":115},{"A":"ALL202－O C2：MTX phase-A【MTX：3g/m2】","B":"１）血液","C":"非表示","__rowNum__":116},{"A":"ALL202－O C2：MTX phase-A【MTX：1.5g/m2】50歳以上","B":"１）血液","__rowNum__":117},{"A":"Aza【皮下注射】","B":"１）血液","__rowNum__":118},{"A":"MTX中等量","B":"１）血液","__rowNum__":119},{"A":"R-Bendamustine療法【２日間】","B":"１）血液","__rowNum__":120},{"A":"VMP療法","B":"１）血液","C":"非表示","__rowNum__":121},{"A":"ATO療法 【１日間】","B":"１）血液","__rowNum__":122},{"A":"ATO療法 【５日間】","B":"１）血液","__rowNum__":123},{"A":"Velcade【皮下：週２回】","B":"１）血液","__rowNum__":124},{"A":"Velcade【皮下：週１回】","B":"１）血液","__rowNum__":125},{"A":"JALSG-ALL202U(Induction)","B":"１）血液","C":"非表示","__rowNum__":126},{"A":"JALSG-ALL202U(Consolidation)","B":"１）血液","C":"非表示","__rowNum__":127},{"A":"GDP療法","B":"１）血液","__rowNum__":128},{"A":"R-GDP療法","B":"１）血液","__rowNum__":129},{"A":"JALSG-ALL202U (Sanctuary)","B":"１）血液","C":"非表示","__rowNum__":130},{"A":"JALSG-ALL202U (Re-induction)","B":"１）血液","C":"非表示","__rowNum__":131},{"A":"VP-16単独療法","B":"１）血液","C":"非表示","__rowNum__":132},{"A":"JALSG-ALL202U (Maintenance①)","B":"１）血液","C":"非表示","__rowNum__":133},{"A":"JALSG-ALL202U (Maintenance②)入院【VCR】","B":"１）血液","C":"非表示","__rowNum__":134},{"A":"JALSG-ALL202U (Maintenance②)入院【VDS】","B":"１）血液","C":"非表示","__rowNum__":135},{"A":"JALSG-ALL202U (Maintenance②)外来【VCR】","B":"１）血液","C":"非表示","__rowNum__":136},{"A":"JALSG-ALL202U (Maintenance②)外来【VDS】","B":"１）血液","C":"非表示","__rowNum__":137},{"A":"JALSG-ALL202U (Maintenance③)","B":"１）血液","C":"非表示","__rowNum__":138},{"A":"JALSG-ALL202U (Maintenance④)入院【VCR】","B":"１）血液","C":"非表示","__rowNum__":139},{"A":"JALSG-ALL202U (Maintenance④)入院【VDS】","B":"１）血液","C":"非表示","__rowNum__":140},{"A":"JALSG-ALL202U (Maintenance④)外来【VCR】","B":"１）血液","C":"非表示","__rowNum__":141},{"A":"JALSG-ALL202U (Maintenance④)外来【VDS】","B":"１）血液","C":"非表示","__rowNum__":142},{"A":"JALSG-ALL208 IMA（C1）（15～59歳）","B":"１）血液","C":"非表示","__rowNum__":143},{"A":"JALSG-ALL208 IMA（C1）（60～64歳）","B":"１）血液","C":"非表示","__rowNum__":144},{"A":"JALSG-ALL208 IMA（C２）","B":"１）血液","C":"非表示","__rowNum__":145},{"A":"JALSG-ALL208 IMA（維持療法）","B":"１）血液","C":"非表示","__rowNum__":146},{"A":"アドセトリス単独療法","B":"１）血液","__rowNum__":147},{"A":"APL204地固め療法（C3：IDA/Ara-C）","B":"１）血液","C":"非表示","__rowNum__":148},{"A":"VcR-CAP療法","B":"１）血液","C":"非表示","__rowNum__":149},{"A":"オファツムマブ療法【初回】（300mg/body）","B":"１）血液","C":"非表示","__rowNum__":150},{"A":"オファツムマブ療法【2～8回目】（週１回：2000mg/body）","B":"１）血液","C":"非表示","__rowNum__":151},{"A":"オファツムマブ療法【9～12回目】（4週毎：2000mg/body）","B":"１）血液","C":"非表示","__rowNum__":152},{"A":"AML_low dose Ara-C","B":"１）血液","C":"非表示","__rowNum__":153},{"A":"THP-COP-E","B":"１）血液","C":"非表示","__rowNum__":154},{"A":"GO療法 【分割投与】","B":"１）血液","__rowNum__":155},{"A":"JALSG ALL213, induction（VCR）","B":"１）血液","__rowNum__":156},{"A":"抗CCR4抗体＋CHOP（VDS）","B":"１）血液","__rowNum__":157},{"A":"ラニムスチン単独投与","B":"１）血液","__rowNum__":158},{"A":"クロファラビン療法【21歳以下：52mg/㎡】","B":"１）血液","C":"非表示","__rowNum__":159},{"A":"ボルテゾミブ（静注）：【21日ｻｲｸﾙ：day1,4,8,11】","B":"１）血液","__rowNum__":160},{"A":"ボルテゾミブ［皮下注］：【21日ｻｲｸﾙ：day1,4,8,11】","B":"１）血液","__rowNum__":161},{"A":"VR-CAP療法","B":"１）血液","C":"非表示","__rowNum__":162},{"A":"PDX単剤","B":"１）血液","__rowNum__":163},{"A":"DBd療法【１サイクル目】","B":"１）血液","__rowNum__":164},{"A":"DBd療法【２・３サイクル目】","B":"１）血液","__rowNum__":165},{"A":"DBd療法【４～８サイクル目】","B":"１）血液","__rowNum__":166},{"A":"DBd療法【９サイクル目以降】","B":"１）血液","__rowNum__":167},{"A":"ニボルマブ","B":"１）血液","__rowNum__":168},{"A":"DLd療法【１サイクル目】","B":"１）血液","__rowNum__":169},{"A":"DLd療法【２サイクル目】","B":"１）血液","__rowNum__":170},{"A":"DLd療法【３～６サイクル目】","B":"１）血液","__rowNum__":171},{"A":"DLd療法【７サイクル目以降】","B":"１）血液","__rowNum__":172},{"A":"JALSG_Ph+ALL213 強化地固め療法","B":"１）血液","C":"非表示","__rowNum__":173},{"A":"JALSG_Ph+ALL213 地固め療法＿Ｃ１","B":"１）血液","__rowNum__":174},{"A":"JALSG_Ph+ALL213 地固め療法＿Ｃ２","B":"１）血液","__rowNum__":175},{"A":"JALSG_Ph+ALL213 維持療法","B":"１）血液","__rowNum__":176},{"A":"G-CHOP 【１サイクル目】","B":"１）血液","__rowNum__":177},{"A":"G-CHOP 【２～６サイクル目】","B":"１）血液","__rowNum__":178},{"A":"Gazyva単剤 【３週間毎】","B":"１）血液","__rowNum__":179},{"A":"G-CVP 【１サイクル目】","B":"１）血液","__rowNum__":180},{"A":"G-CVP 【２～８サイクル目】","B":"１）血液","__rowNum__":181},{"A":"G-Bendamustine 【１サイクル目】","B":"１）血液","__rowNum__":182},{"A":"G-Bendamustine 【２～６サイクル目】","B":"１）血液","__rowNum__":183},{"A":"Gazyva維持 【８週間毎】","B":"１）血液","__rowNum__":184},{"A":"Gazyva単剤 【１サイクル目】","B":"１）血液","__rowNum__":185},{"A":"IO療法 【１サイクル目】","B":"１）血液","__rowNum__":186},{"A":"IO療法 ★寛解★【２～６サイクル目】","B":"１）血液","__rowNum__":187},{"A":"IO療法 ★非寛解★【２～６サイクル目】","B":"１）血液","__rowNum__":188},{"A":"Ｋｄ療法 【１サイクル目：週２回】","B":"１）血液","__rowNum__":189},{"A":"Ｋｄ療法 【２サイクル目以降：週２回】","B":"１）血液","__rowNum__":190},{"A":"ロミデプシン療法","B":"１）血液","__rowNum__":191},{"A":"MM_E-Ld療法 【１・２サイクル目】","B":"１）血液","__rowNum__":192},{"A":"MM_E-Ld療法 【３サイクル目以降】","B":"１）血液","__rowNum__":193},{"A":"MM_E-Pd療法 【１・２サイクル目】","B":"１）血液","__rowNum__":194},{"A":"MM_E-Pd療法 【３サイクル目以降】","B":"１）血液","__rowNum__":195},{"A":"HL_A+AVD療法","B":"１）血液","__rowNum__":196},{"A":"T-NHL_A+CHP療法","B":"１）血液","__rowNum__":197},{"A":"KRd療法【１サイクル目】","B":"１）血液","__rowNum__":198},{"A":"KRd療法【２～１２サイクル目】","B":"１）血液","__rowNum__":199},{"A":"KRd療法【１３サイクル目以降】","B":"１）血液","__rowNum__":200},{"A":"Ｋｄ療法 【１サイクル目：週１回】","B":"１）血液","__rowNum__":201},{"A":"Ｋｄ療法 【２サイクル目以降：週１回】","B":"１）血液","__rowNum__":202},{"A":"MM＿IsaPd【１サイクル目】","B":"１）血液","__rowNum__":203},{"A":"MM＿IsaPd【２サイクル目以降】","B":"１）血液","__rowNum__":204},{"A":"IP療法（CDDP/CPT-11）","B":"２）呼吸器","C":"非表示","__rowNum__":205},{"A":"CDDP/ETP療法","B":"２）呼吸器","E":"2～8時間","F":"３週間ごと (d1, d2, d3)","H":"シスプラチン","I":"エトポシド","__rowNum__":206},{"A":"CBDCA/ETP（AUC：4）","B":"２）呼吸器","C":"非表示","__rowNum__":207},{"A":"CBDCA/ETP（AUC：4.5）","B":"２）呼吸器","C":"非表示","__rowNum__":208},{"A":"CBDCA/ETP（poor risk）","B":"２）呼吸器","E":"2～4時間","F":"３週間ごと (d1, d2, d3)","H":"カルボプラチン","I":"エトポシド","__rowNum__":209},{"A":"CPT-11","B":"２）呼吸器","C":"非表示","__rowNum__":210},{"A":"AMR","B":"２）呼吸器","E":"1時間","F":"３週間ごと (d1, d2, d3)","H":"アムルビシン","__rowNum__":211},{"A":"CBDCA/PTX（浸潤性胸腺腫）","B":"２）呼吸器","C":"非表示","__rowNum__":212},{"A":"CBDCA(AUC：5)/PTX","B":"２）呼吸器","C":"非表示","__rowNum__":213},{"A":"CBDCA(AUC：5.5)/PTX","B":"２）呼吸器","C":"非表示","__rowNum__":214},{"A":"CBDCA/PTX","B":"２）呼吸器","E":"5時間","F":"３週間ごと (d1)","H":"カルボプラチン","I":"パクリタキセル","__rowNum__":215},{"A":"CDDP/GEM療法","B":"２）呼吸器","C":"非表示","__rowNum__":216},{"A":"CDDP/VNR療法","B":"２）呼吸器","E":"1～8時間","F":"３週間ごと (d1, d8)","H":"シスプラチン","I":"ビノレルビン","__rowNum__":217},{"A":"CDDP/DTX療法","B":"２）呼吸器","C":"非表示","__rowNum__":218},{"A":"DTX","B":"２）呼吸器","E":"2時間","F":"３週間ごと (d1)","H":"ドセタキセル","__rowNum__":219},{"A":"VNR","B":"２）呼吸器","C":"非表示","__rowNum__":220},{"A":"GEM","B":"２）呼吸器","C":"非表示","__rowNum__":221},{"A":"CDDP/PEM療法","B":"２）呼吸器","E":"8時間","F":"３週間ごと (d1)","H":"シスプラチン","I":"ペメトレキセド","__rowNum__":222},{"A":"PEM","B":"２）呼吸器","E":"1時間","F":"３週間ごと (d1)","H":"ペメトレキセド","__rowNum__":223},{"A":"CBDCA/PEM （poor risk)","B":"２）呼吸器","E":"3時間","F":"３週間ごと (d1)","H":"カルボプラチン","I":"ペメトレキセド","__rowNum__":224},{"A":"CBDCA/GEM （q：3w～4w）","B":"２）呼吸器","C":"非表示","__rowNum__":225},{"A":"CBDCA/GEM （biweekly）","B":"２）呼吸器","C":"非表示","__rowNum__":226},{"A":"GEM/VNR","B":"２）呼吸器","C":"非表示","__rowNum__":227},{"A":"CBDCA/DTX","B":"２）呼吸器","C":"非表示","__rowNum__":228},{"A":"hypotonic cysplatin","B":"２）呼吸器","C":"非表示","__rowNum__":229},{"A":"CBDCA/PTX/BV","B":"２）呼吸器","E":"6～7時間","F":"３週間ごと (d1)","H":"カルボプラチン","I":"パクリタキセル","J":"ベバシズマブ","__rowNum__":230},{"A":"CBDCA/DTX/BV","B":"２）呼吸器","C":"非表示","__rowNum__":231},{"A":"BV維持療法","B":"２）呼吸器","E":"1時間","F":"３週間ごと (d1)","H":"ベバシズマブ","__rowNum__":232},{"A":"ノギテカン（初期量：1.0mg/㎡）","B":"２）呼吸器","C":"非表示","__rowNum__":233},{"A":"ノギテカン（増量版：1.2mg/㎡）","B":"２）呼吸器","C":"非表示","__rowNum__":234},{"A":"CBDCA/PEM/BV","B":"２）呼吸器","E":"3～4時間","F":"３週間ごと (d1)","H":"カルボプラチン","I":"ペメトレキセド","J":"ベバシズマブ","__rowNum__":235},{"A":"ノギテカン（減量版：0.8mg/㎡）","B":"２）呼吸器","C":"非表示","__rowNum__":236},{"A":"CBDCA/TS-1","B":"２）呼吸器","E":"2時間","F":"３週間ごと (d1)","H":"カルボプラチン","I":"S-1","__rowNum__":237},{"A":"CBDCA/CPT-11","B":"２）呼吸器","C":"非表示","__rowNum__":238},{"A":"CBDCA(AUC：4)/CPT-11","B":"２）呼吸器","C":"非表示","__rowNum__":239},{"A":"PEM/BV","B":"２）呼吸器","E":"1～2時間","F":"３週間ごと (d1)","H":"ペメトレキセド","I":"ベバシズマブ","__rowNum__":240},{"A":"Weekly CBDCA/PTX/RT","B":"２）呼吸器","E":"3時間","F":"１週間ごと (d1)","H":"カルボプラチン","I":"パクリタキセル","__rowNum__":241},{"A":"CDDP/TS-1 （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":242},{"A":"CPAパルス療法","B":"２）呼吸器","E":"1時間","F":"４週間ごと (d1)","H":"シクロホスファミド","__rowNum__":243},{"A":"CDDP/S-1/RT （short hydration）","B":"２）呼吸器","E":"5時間","F":"４週間ごと (d1)","H":"シスプラチン","I":"S-1","__rowNum__":244},{"A":"CDDP/VNR （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":245},{"A":"DTX/BV","B":"２）呼吸器","C":"非表示","__rowNum__":246},{"A":"CDDP/VNR/TRT （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":247},{"A":"CDDP/CPT-11 （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":248},{"A":"CDDP/GEM （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":249},{"A":"CDDP/PEM （short hydration）","B":"２）呼吸器","C":"非表示","__rowNum__":250},{"A":"CBDCA/nab-PTX","B":"２）呼吸器","E":"1～3時間","F":"３週間 (d1, d8, d15)","H":"カルボプラチン","I":"ナブパクリタキセル","__rowNum__":251},{"A":"CAMP","B":"２）呼吸器","C":"非表示","__rowNum__":252},{"A":"NSCLC-CBDCA/PTX/RT (地固め)","B":"２）呼吸器","C":"非表示","__rowNum__":253},{"A":"weekly nab-PTX","B":"２）呼吸器","E":"1時間","F":"４週間 (d1, d8, d15)","H":"ナブパクリタキセル","__rowNum__":254},{"A":"CBDCA/TRT","B":"２）呼吸器","C":"非表示","__rowNum__":255},{"A":"Nivolumab","B":"２）呼吸器","E":"1時間","F":"２週間 (d1)","H":"ニボルマブ","__rowNum__":256},{"A":"SCLC_Split CDDP+ETP(poor risk)","B":"２）呼吸器","C":"非表示","__rowNum__":257},{"A":"DTX+Ramucirumab","B":"２）呼吸器","E":"3時間","F":"３週間 (d1)","H":"ドセタキセル","I":"ラムシルマブ","__rowNum__":258},{"A":"Pembrolizumab","B":"２）呼吸器","E":"1時間","F":"３週間 (d1)","H":"ペムブロリズマブ","__rowNum__":259},{"A":"Atezolizumab療法","B":"２）呼吸器","E":"1時間","F":"３週間 (d1)","H":"アテゾリズマブ","__rowNum__":260},{"A":"CDGP＋DTX","B":"２）呼吸器","E":"3時間","F":"３週間 (d1)","H":"ネダプラチン","I":"ドセタキセル","__rowNum__":261},{"A":"Durvalumab","B":"２）呼吸器","E":"1時間","F":"２週間 (d1)","H":"デュルバルマブ","__rowNum__":262},{"A":"CBDCA＋PTX＋BV＋Atezolizumab","B":"２）呼吸器","E":"7～8時間","F":"３週間 (d1)","H":"カルボプラチン","I":"パクリタキセル","J":"ベバシズマブ","K":"アテゾリズマブ","__rowNum__":263},{"A":"BV＋Atezolizumab 【maintenance】","B":"２）呼吸器","E":"1時間","F":"３週間 (d1)","H":"ベバシズマブ","I":"アテゾリズマブ","__rowNum__":264},{"A":"CDDP/PEM/Pembrolizumab（short hydration）","B":"２）呼吸器","E":"6時間","F":"３週間 (d1)","H":"シスプラチン","I":"ペメトレキセド","J":"ペムブロリズマブ","__rowNum__":265},{"A":"CBDCA/PEM/Pembrolizumab","B":"２）呼吸器","E":"3時間","F":"３週間 (d1)","H":"カルボプラチン","I":"ペメトレキセド","J":"ペムブロリズマブ","__rowNum__":266},{"A":"PEM/Pembrolizumab【維持療法】","B":"２）呼吸器","E":"2時間","F":"３週間 (d1)","H":"ペメトレキセド","I":"ペムブロリズマブ","__rowNum__":267},{"A":"CBDCA/nab-PTX/Pembrolizumab","B":"２）呼吸器","E":"1～4時間","F":"３週間 (d1, d8, d15)","H":"カルボプラチン","I":"ナブパクリタキセル","J":"ペムブロリズマブ","__rowNum__":268},{"A":"CBDCA/ETP/Atezolizumab","B":"２）呼吸器","E":"2～4時間","F":"３週間 (d1, d2, d3)","H":"カルボプラチン","I":"エトポシド","J":"アテゾリズマブ","__rowNum__":269},{"A":"【６W】Pembrolizumab [400mg]","B":"２）呼吸器","E":"1時間","F":"６週間 (d1)","H":"ペムブロリズマブ","__rowNum__":270},{"A":"NSCLC-CBDCA/PTX/RT 【weekly】","B":"２）呼吸器","C":"非表示","__rowNum__":271},{"A":"NSCLC-CBDCA/PTX/RT (地固め)","B":"２）呼吸器","C":"非表示","__rowNum__":272},{"A":"中皮腫_GEM","B":"２）呼吸器","C":"非表示","__rowNum__":273},{"A":"胃がん_Ramcirumab","B":"３）胃","E":"1.5時間","F":"２週間ごと (d1)","H":"ラムシルマブ","__rowNum__":274},{"A":"胃がん_Ramcirumab＋PTX（weekly）","B":"３）胃","D":"ラムシルマブ終了後の経過観察は20210427化学療法委員会にて不要とすることを決めた。","E":"1.5～3時間","F":"４週間ごと (d1, d8, d15)","H":"ラムシルマブ","I":"パクリタキセル","__rowNum__":275},{"A":"FP療法 （5-FUのみ/ポート用）","B":"３）胃","C":"非表示","E":"4+120時間","__rowNum__":276},{"A":"胃がん_5FU_PVI","B":"３）胃","C":"非表示","E":"24時間持続","__rowNum__":277},{"A":"胃がん_Nivolumab","B":"３）胃","E":"1時間","F":"２週間ごと (d1)","H":"ニボルマブ","__rowNum__":278},{"A":"胃がん_FP療法【ポート用】","B":"３）胃","E":"4+120時間","F":"３週間ごと (d1)","H":"シスプラチン","I":"フルオロウラシル","__rowNum__":279},{"A":"胃がん_HER＋FP療法（１サイクル目）【ポート用】","B":"３）胃","E":"6+120時間","F":"３週間 (d1)","H":"トラスツズマブ","I":"シスプラチン","J":"フルオロウラシル","__rowNum__":280},{"A":"胃がん_HER＋FP療法（２サイクル目以降）【ポート用】","B":"３）胃","E":"5+120時間","F":"３週間ごと (d1)","H":"トラスツズマブ","I":"シスプラチン","J":"フルオロウラシル","__rowNum__":281},{"A":"S-1/CDDP","B":"３）胃","D":"■S-1の内服は、day1~day21。シスプラチン投与時(day8)には、S-1内服は継続されていることを確認する。","E":"3時間","F":"５週間ごと (d8)","H":"シスプラチン","I":"S-1","__rowNum__":282},{"A":"weekly PTX","B":"３）胃","E":"2時間","F":"４週間ごと (d1, d8, d15)","H":"パクリタキセル","__rowNum__":283},{"A":"FP療法（CDDP/5-FU）【末梢用】","B":"３）胃","E":"6+120時間","F":"３週間ごと (d1)","H":"シスプラチン","I":"フルオロウラシル","__rowNum__":284},{"A":"DTX","B":"３）胃","E":"2時間","F":"３週間ごと (d1)","H":"ドセタキセル","__rowNum__":285},{"A":"CPT-11/CDDP","B":"３）胃","C":"非表示","__rowNum__":286},{"A":"HER/XP （初回）","B":"３）胃","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"7時間","F":"３週間 (d1)","H":"トラスツズマブ","I":"シスプラチン","J":"カペシタビン","__rowNum__":287},{"A":"HER/XP （２回目以降）","B":"３）胃","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"7時間","F":"３週間ごと (d1)","H":"トラスツズマブ","I":"シスプラチン","J":"カペシタビン","__rowNum__":288},{"A":"MF療法","B":"３）胃","C":"非表示","__rowNum__":289},{"A":"DOX療法","B":"３）胃","C":"非表示","__rowNum__":290},{"A":"nab-PTX療法","B":"３）胃","C":"非表示","__rowNum__":291},{"A":"5FU－PVI療法（３日間レジメン）","B":"３）胃","C":"非表示","__rowNum__":292},{"A":"G-SOX療法","B":"３）胃","D":"■S-1の内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3時間","F":"３週間ごと (d1)","H":"オキサリプラチン","I":"S-1","__rowNum__":293},{"A":"胃癌_XP療法","B":"３）胃","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"5時間","F":"３週間ごと (d1)","H":"シスプラチン","I":"カペシタビン","__rowNum__":294},{"A":"XELOX（胃がん）","B":"３）胃","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3時間","F":"３週間ごと (d1)","H":"オキサリプラチン","I":"カペシタビン","__rowNum__":295},{"A":"Ram＋nab-PTX","B":"３）胃","E":"1～3時間","F":"４週間ごと (d1, d8, d15)","H":"ラムシルマブ","I":"ナブパクリタキセル","__rowNum__":296},{"A":"食道がん_FP療法","B":"３）食道","E":"8+120時間","F":"４週間ごと (d1-5)","H":"シスプラチン","I":"フルオロウラシル","__rowNum__":297},{"A":"Dox療法","B":"３）食道","C":"非表示","__rowNum__":298},{"A":"【食道がん】 ｗPTX療法 （６投１休）","B":"３）食道","E":"2時間","F":"７週間ごと(d1,d8,d15,d22,d29,d36)","H":"パクリタキセル","__rowNum__":299},{"A":"食道がん_DTX療法","B":"３）食道","C":"非表示","__rowNum__":300},{"A":"【食道がん】ｗPTX（6投1休）","B":"３）食道","C":"非表示","__rowNum__":301},{"A":"【食道癌：CV用】 CDGP＋5-FU＋RT","B":"３）食道","E":"2+120時間","F":"５週間ごと (d1)","H":"ネダプラチン","I":"フルオロウラシル","__rowNum__":302},{"A":"Ramucirumab+FOLFIRI","B":"３）大腸","E":"4+46時間","F":"２週間ごと (d1)","H":"ラムシルマブ","I":"イリノテカン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":303},{"A":"大腸がん_CPT-11（biweekly）","B":"３）大腸","E":"2時間","F":"２週間ごと (d1)","H":"イリノテカン","__rowNum__":304},{"A":"ｓLV5FU2療法","B":"３）大腸","E":"3+46時間","F":"２週間ごと (d1)","H":"レボホリナート","I":"フルオロウラシル","__rowNum__":305},{"A":"大腸がん_IRIS＋BV","B":"３）大腸","E":"3～4時間","F":"４週間ごと (d1, d15)","H":"ベバシズマブ","I":"イリノテカン","J":"ベバシズマブ","K":"S-1","__rowNum__":306},{"A":"大腸がん_mCapeIRI＋BV","B":"３）大腸","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3～4時間","F":"３週間ごと (d1)","H":"ベバシズマブ","I":"イリノテカン","J":"カペシタビン","K":"ベバシズマブ","__rowNum__":307},{"A":"大腸がん_Pmab＋CPT-11","B":"３）大腸","E":"3時間","F":"２週間ごと (d1)","H":"パニツムマブ","I":"イリノテカン","__rowNum__":308},{"A":"FOLFOX6 （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":309},{"A":"FOLFOX6 （ポート）","B":"３）大腸","E":"3+46時間","F":"２週間ごと (d1)","H":"オキサリプラチン","I":"レボホリナート","J":"フルオロウラシル","__rowNum__":310},{"A":"BV【5mg/kg】＋FOLFOX6 （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":311},{"A":"BV【10mg/kg】＋FOLFOX6 （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":312},{"A":"BV【5mg/kg】＋FOLFOX6 （ポート）","B":"３）大腸","E":"3～4+46時間","F":"２週間ごと (d1)","H":"ベバシズマブ","I":"オキサリプラチン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":313},{"A":"BV【10mg/kg】＋FOLFOX6 （ポート）","B":"３）大腸","C":"非表示","__rowNum__":314},{"A":"FOLFIRI （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":315},{"A":"FOLFIRI （ポート）","B":"３）大腸","E":"3+46時間","F":"２週間ごと (d1)","H":"イリノテカン","I":"レボホリナート","J":"フルオロウラシル","__rowNum__":316},{"A":"BV【5mg/kg】＋FOLFIRI （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":317},{"A":"BV【10mg/kg】＋FOLFIRI （末梢投与）","B":"３）大腸","C":"非表示","__rowNum__":318},{"A":"BV【5mg/kg】＋FOLFIRI （ポート）","B":"３）大腸","E":"4～5+46時間","F":"２週間ごと (d1)","H":"ベバシズマブ","I":"イリノテカン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":319},{"A":"BV【10mg/kg】＋FOLFIRI （ポート）","B":"３）大腸","C":"非表示","__rowNum__":320},{"A":"XELOX","B":"３）大腸","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3時間","F":"３週間ごと (d1)","H":"オキサリプラチン","I":"カペシタビン","__rowNum__":321},{"A":"BV＋XELOX","B":"３）大腸","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3～4時間","F":"３週間ごと (d1)","H":"ベバシズマブ","I":"オキサリプラチン","J":"カペシタビン","__rowNum__":322},{"A":"BV＋ゼローダ","B":"３）大腸","D":"■カペシタビンの内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"2～3時間","F":"３週間ごと (d1)","H":"ベバシズマブ","I":"カペシタビン","__rowNum__":323},{"A":"SOX","B":"３）大腸","D":"■S-1の内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"3時間","F":"３週間ごと (d1)","H":"オキサリプラチン","I":"S-1","__rowNum__":324},{"A":"cetuximab （初回）","B":"３）大腸","E":"3時間","F":"１週間 (d1)","H":"セツキシマブ","__rowNum__":325},{"A":"cetuximab （２回目以降）","B":"３）大腸","E":"2時間","F":"１週間ごと (d1)","H":"セツキシマブ","__rowNum__":326},{"A":"cetuximab/ＣＰＴ-11 （１サイクル目）","B":"３）大腸","E":"2~5時間","F":"７週間 (d1,d8,d15,d22,d29,d36,d43)","H":"セツキシマブ","I":"イリノテカン","__rowNum__":327},{"A":"cetuximab/ＣＰＴ-11 （２サイクル目以降）","B":"３）大腸","E":"2~4時間","F":"７週間ごと (d1,d8,d15,d22,d29,d36,d43)","H":"セツキシマブ","I":"イリノテカン","__rowNum__":328},{"A":"ｓLV5FU2療法","B":"３）大腸","C":"非表示","__rowNum__":329},{"A":"パニツムマブ単独療法","B":"３）大腸","E":"1時間","F":"２週間ごと (d1)","H":"パニツムマブ","__rowNum__":330},{"A":"SOX/BV","B":"３）大腸","D":"■S-1の内服は、day1夕からday15朝まで行われるため、内服を確認する。","E":"2～4時間","F":"３週間ごと (d1)","H":"ベバシズマブ","I":"オキサリプラチン","__rowNum__":331},{"A":"ｃ-mab+FOLFOX（1サイクル目）","B":"３）大腸","E":"2～6+46時間","F":"２週間 (d1, d8)","H":"セツキシマブ","I":"オキサリプラチン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":332},{"A":"ｃ-mab+FOLFOX（2サイクル目以降）","B":"３）大腸","E":"2～5+46時間","F":"２週間ごと (d1, d8)","H":"セツキシマブ","I":"オキサリプラチン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":333},{"A":"ｃ-mab+FOLFIRI（1サイクル目）","B":"３）大腸","E":"2～6+46時間","F":"２週間(d1, d8)","H":"セツキシマブ","I":"イリノテカン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":334},{"A":"ｃ-mab+FOLFIRI（2サイクル目以降）","B":"３）大腸","E":"2～5+46時間","F":"２週間ごと (d1, d8)","H":"セツキシマブ","I":"イリノテカン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":335},{"A":"Panitumumab＋mFOLFOX6","B":"３）大腸","E":"4+46時間","F":"２週間ごと (d1)","H":"パニツムマブ","I":"オキサリプラチン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":336},{"A":"Panitumumab＋FOLFIRI","B":"３）大腸","E":"4+46時間","F":"２週間ごと (d1)","H":"パニツムマブ","I":"イリノテカン","J":"レボホリナート","K":"フルオロウラシル","__rowNum__":337},{"A":"Panitumumab＋CPT-11","B":"３）大腸","E":"3時間","F":"２週間ごと (d1)","H":"パニツムマブ","I":"イリノテカン","__rowNum__":338},{"A":"肛門管がん_MMC+5-FU","B":"３）肛門管","C":"非表示","__rowNum__":339},{"A":"肛門管がん_MMC+cape","B":"３）肛門管","C":"非表示","__rowNum__":340},{"A":"CDDP/GEM療法","B":"４）胆管","C":"非表示","__rowNum__":341},{"A":"CDDP/GEM療法【Modified】","B":"４）胆管","E":"4時間","F":"３週間ごと (d1, d8)","H":"シスプラチン","I":"ゲムシタビン","__rowNum__":342},{"A":"GEM+RT療法","B":"４）膵","C":"非表示","__rowNum__":343},{"A":"GEM療法 【グラニセトロン】","B":"４）膵","E":"1時間","F":"４週間ごと (d1, d8, d15)","H":"ゲムシタビン","__rowNum__":344},{"A":"GEM療法 【パロノセトロン】","B":"４）膵","E":"1時間","F":"４週間ごと (d1, d8, d15)","H":"ゲムシタビン","__rowNum__":345},{"A":"GEM療法 【パロノセトロン＋ホスアプレピタント】","B":"４）膵","E":"2時間","F":"４週間ごと (d1, d8, d15)","H":"ゲムシタビン","__rowNum__":346},{"A":"FOLFIRINOX","B":"４）膵","E":"5+46時間","F":"２週間ごと (d1)","H":"オキサリプラチン","I":"レボホリナート","J":"イリノテカン","K":"フルオロウラシル","__rowNum__":347},{"A":"GEM+Nab-paclitaxel","B":"４）膵","E":"2時間","F":"４週間ごと (d1, d8, d15)","H":"ナブパクリタキセル","I":"ゲムシタビン","__rowNum__":348},{"A":"nalIRI＋5-FU＋l-LV","B":"４）膵","E":"5+46時間","F":"２週間ごと (d1)","H":"リポソーム化イリノテカン","I":"レボホリナート","J":"フルオロウラシル","__rowNum__":349},{"A":"胸腺がん_PTX【weekly】","B":"５）胸腺","C":"非表示","__rowNum__":350},{"A":"胸腺がん_CBDCA＋PTX（AUC：6）","B":"５）胸腺","C":"非表示","__rowNum__":351},{"A":"weekly PTX療法","B":"５）乳腺","E":"2時間","F":"４週間ごと (d1, d8, d15)","H":"パクリタキセル","__rowNum__":352},{"A":"Adjuvant HER （初回）","B":"５）乳腺","E":"2時間","F":"３週間 (d1)","H":"トラスツズマブ","__rowNum__":353},{"A":"Adjuvant HER （２回目以降）","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"トラスツズマブ","__rowNum__":354},{"A":"再発 HER （１～３回目）","B":"５）乳腺","C":"非表示","__rowNum__":355},{"A":"再発 HER （４回目以降）","B":"５）乳腺","C":"非表示","__rowNum__":356},{"A":"VNR療法","B":"５）乳腺","E":"0.5時間","F":"３週間ごと (d1, d8)","H":"ビノレルビン","__rowNum__":357},{"A":"FEC60","B":"５）乳腺","C":"非表示","__rowNum__":358},{"A":"FEC100","B":"５）乳腺","C":"非表示","__rowNum__":359},{"A":"GEM療法","B":"５）乳腺","E":"1時間","F":"３週間ごと (d1, d8)","H":"ゲムシタビン","__rowNum__":360},{"A":"PTX/GEM療法","B":"５）乳腺","C":"非表示","__rowNum__":361},{"A":"AC療法","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"ピラルビシン","I":"シクロホスファミド","__rowNum__":362},{"A":"AC＋ゾレドロン酸","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"ピラルビシン","I":"シクロホスファミド","__rowNum__":363},{"A":"HER/PTX （１～３回目）","B":"５）乳腺","E":"3時間","F":"４週間 (d1, d8, d15)","H":"トラスツズマブ","I":"パクリタキセル","__rowNum__":364},{"A":"HER/PTX （４回目以降）","B":"５）乳腺","E":"3時間","F":"４週間ごと (d1, d8, d15)","H":"トラスツズマブ","I":"パクリタキセル","__rowNum__":365},{"A":"HER/VNR （１、２回目）","B":"５）乳腺","E":"2時間","F":"３週間 (d1, d8)","H":"トラスツズマブ","I":"ビノレルビン","__rowNum__":366},{"A":"HER/VNR （３回目以降）","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1, d8)","H":"トラスツズマブ","I":"ビノレルビン","__rowNum__":367},{"A":"nab-PTX療法","B":"５）乳腺","C":"非表示","__rowNum__":368},{"A":"nab-PTX療法 【tri-weekly】","B":"５）乳腺","E":"1時間","F":"３週間ごと (d1)","H":"ナブパクリタキセル","__rowNum__":369},{"A":"EC療法 【tri-weekly】","B":"５）乳腺","C":"非表示","__rowNum__":370},{"A":"DTX療法 【75mg/㎡，tri-weekly】","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"ドセタキセル","__rowNum__":371},{"A":"HER/TC （初回）","B":"５）乳腺","C":"非表示","__rowNum__":372},{"A":"HER/TC （２回目以降）","B":"５）乳腺","C":"非表示","__rowNum__":373},{"A":"weekly PTX + biweekly BV療法","B":"５）乳腺","C":"非表示","__rowNum__":374},{"A":"ハラヴェン療法","B":"５）乳腺","E":"0.5時間","F":"３週間ごと (d1, d8)","H":"エリブリン","__rowNum__":375},{"A":"【初回】パージェタ＋ハーセプチン＋ドセタキセル","B":"５）乳腺","E":"4時間","F":"３週間 (d1)","H":"ペルツズマブ","I":"トラスツズマブ","J":"ドセタキセル","__rowNum__":376},{"A":"【２回以降】パージェタ＋ハーセプチン＋ドセタキセル","B":"５）乳腺","E":"3時間","F":"３週間ごと (d1)","H":"ペルツズマブ","I":"トラスツズマブ","J":"ドセタキセル","__rowNum__":377},{"A":"【初回】パージェタ＋ハーセプチン","B":"５）乳腺","C":"非表示","__rowNum__":378},{"A":"【２回以降】パージェタ＋ハーセプチン","B":"５）乳腺","C":"非表示","__rowNum__":379},{"A":"カドサイラ","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"トラスツズマブ　エムタンシン","__rowNum__":380},{"A":"ｗHER＋GEM（１サイクル目）","B":"５）乳腺","C":"非表示","__rowNum__":381},{"A":"ｗHER＋GEM（２サイクル目以降）","B":"５）乳腺","C":"非表示","__rowNum__":382},{"A":"【1ｻｲｸﾙ目】PER＋HER＋ERI","B":"５）乳腺","E":"0.5～3時間","F":"３週間 (d1, d8)","H":"ペルツズマブ","I":"トラスツズマブ","J":"エリブリン","__rowNum__":383},{"A":"【2ｻｲｸﾙ目以降】PER＋HER＋ERI","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1, d8)","H":"ペルツズマブ","I":"トラスツズマブ","J":"エリブリン","__rowNum__":384},{"A":"BV/nab-PTX","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"ベバシズマブ","I":"ナブパクリタキセル","__rowNum__":385},{"A":"ｄｄ ＡＣ療法","B":"５）乳腺","E":"2時間","F":"２週間ごと (d1)","H":"ピラルビシン","I":"シクロホスファミド","__rowNum__":386},{"A":"ｄｄ ＰＴＸ療法","B":"５）乳腺","E":"4時間","F":"２週間ごと (d1)","H":"パクリタキセル","__rowNum__":387},{"A":"【初回】TCH療法（DTX/CBDCA/HER）","B":"５）乳腺","E":"5時間","F":"３週間ごと (d1)","H":"トラスツズマブ","I":"ドセタキセル","J":"カルボプラチン","__rowNum__":388},{"A":"【２回目以降】TCH療法（DTX/CBDCA/HER）","B":"５）乳腺","E":"4時間","F":"３週間ごと (d1)","H":"トラスツズマブ","I":"ドセタキセル","J":"カルボプラチン","__rowNum__":389},{"A":"TC療法","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1)","H":"シクロホスファミド","I":"ドセタキセル","__rowNum__":390},{"A":"3wHER＋wPTX（１サイクル目）","B":"５）乳腺","E":"2～3時間","F":"３週間ごと (d1, d8, d15)","H":"トラスツズマブ","I":"パクリタキセル","__rowNum__":391},{"A":"3wHER＋wPTX（２サイクル目以降）","B":"５）乳腺","E":"2時間","F":"３週間ごと (d1, d8, d15)","H":"トラスツズマブ","I":"パクリタキセル","__rowNum__":392},{"A":"【初回】TCHP療法（DTX/CBDCA/HER/PER）","B":"５）乳腺","E":"6時間","F":"３週間ごと (d1)","H":"ドセタキセル","I":"カルボプラチン","J":"ペルツズマブ","K":"トラスツズマブ","__rowNum__":393},{"A":"【２回目以降】TCHP療法（DTX/CBDCA/HER/PER）","B":"５）乳腺","E":"4時間","F":"３週間ごと (d1)","H":"ドセタキセル","I":"カルボプラチン","J":"ペルツズマブ","K":"トラスツズマブ","__rowNum__":394},{"A":"【NET（NEC)】 CDDP/ETP","B":"６）神経内分泌腫瘍","C":"非表示","__rowNum__":395},{"A":"NEC_Split CDDP+ETP （poor risk）","B":"６）神経内分泌腫瘍","C":"非表示","__rowNum__":396},{"A":"NEC_CE （poor risk）","B":"６）神経内分泌腫瘍","C":"非表示","__rowNum__":397},{"A":"NEC_CPT-11【weekly】","B":"６）神経内分泌腫瘍","C":"非表示","__rowNum__":398},{"A":"IFM infusional 【軟部腫瘍】","B":"７）肉腫","C":"非表示","__rowNum__":399},{"A":"【３W】 Pembrolizumab [200mg/body]","B":"８）癌種問わず","E":"1時間","F":"３週間ごと (d1)","H":"ペムブロリズマブ","__rowNum__":400},{"A":"【６W】 Pembrolizumab [400mg/body]","B":"８）癌種問わず","E":"1時間","F":"６週間ごと (d1)","H":"ペムブロリズマブ","__rowNum__":401},{"A":"原発不明癌_CBDCA/PTX","B":"８）原発不明","C":"非表示","__rowNum__":402},{"A":"原発不明癌_GEM","B":"８）原発不明","C":"非表示","__rowNum__":403},{"A":"ｲﾝﾌﾘｷｼﾏﾌﾞ療法 【１ｻｲｸﾙ目：5mg/kg】","B":"９）炎症性腸疾患","E":"2時間","F":"14週間 (d1, d15, d43)","H":"インフリキシマブ","__rowNum__":404},{"A":"ｲﾝﾌﾘｷｼﾏﾌﾞ維持療法 【5mg/kg】","B":"９）炎症性腸疾患","E":"2時間","F":"８週間ごと (d1)","H":"インフリキシマブ","__rowNum__":405},{"A":"ｲﾝﾌﾘｷｼﾏﾌﾞ維持療法 【10mg/kg】","B":"９）炎症性腸疾患","E":"2時間","F":"８週間 ごと(d1)","H":"インフリキシマブ","__rowNum__":406},{"A":"ｲﾝﾌﾘｷｼﾏﾌﾞ維持療法 【4週間：5mg/kg】","B":"９）炎症性腸疾患","E":"2時間","F":"４週間ごと (d1)","H":"インフリキシマブ","__rowNum__":407},{"A":"ステラーラ導入療法【55kg以下】","B":"９）炎症性腸疾患","E":"1時間","F":"16週間 (d1, (d57))","H":"ウステキヌマブ","__rowNum__":408},{"A":"ステラーラ導入療法【55kg超～85kg以下】","B":"９）炎症性腸疾患","E":"1時間","F":"16週間 (d1, (d57))","H":"ウステキヌマブ","__rowNum__":409},{"A":"ステラーラ導入療法【85kg超】","B":"９）炎症性腸疾患","E":"1時間","F":"16週間 (d1, (d57))","H":"ウステキヌマブ","__rowNum__":410},{"A":"ステラーラ維持療法【12週間隔】","B":"９）炎症性腸疾患","E":"-","F":"12週間ごと (d1)","H":"ウステキヌマブ","__rowNum__":411},{"A":"ステラーラ維持療法【8週間隔】","B":"９）炎症性腸疾患","E":"-","F":"８週間ごと (d1)","H":"ウステキヌマブ","__rowNum__":412},{"A":"エンタイビオ 【１サイクル目】","B":"９）炎症性腸疾患","E":"1時間","F":"14週間 (d1, d15, d43)","H":"ベドリズマブ","__rowNum__":413},{"A":"エンタイビオ 【２サイクル目以降】","B":"９）炎症性腸疾患","E":"1時間","F":"８週間ごと (d1)","H":"ベドリズマブ","__rowNum__":414},{"A":"BV+Atezolizumab","B":"４）肝","E":"2～3時間","F":"３週間ごと (d1)","H":"アテゾリズマブ","I":"ベバシズマブ","__rowNum__":415},{"A":"GEM療法","B":"分類確認未","E":"1時間","F":"４週間ごと (d1, d8, d15)","H":"ゲムシタビン","__rowNum__":416},{"A":"TC療法（AUC：6）","B":"分類確認未","C":"非表示","__rowNum__":417},{"A":"TC療法（AUC：5.5）","B":"分類確認未","C":"非表示","__rowNum__":418},{"A":"TC療法（AUC：6）","B":"分類確認未","C":"非表示","__rowNum__":419},{"A":"TC療法（AUC：6.5）","B":"分類確認未","C":"非表示","__rowNum__":420},{"A":"TC療法（AUC：7）","B":"分類確認未","C":"非表示","__rowNum__":421},{"A":"TC療法（AUC：7.5）","B":"分類確認未","C":"非表示","__rowNum__":422},{"A":"CPT-11 （１サイクル：２回）","B":"分類確認未","E":"2時間","F":"５週間ごと (d1, d15)","H":"イリノテカン","__rowNum__":423},{"A":"CPT-11 （１サイクル：３回）","B":"分類確認未","E":"2時間","F":"７週間ごと (d1, d15, d29)","H":"イリノテカン","__rowNum__":424},{"A":"GS療法","B":"分類確認未","C":"非表示","__rowNum__":425}];
var initContents1 = [{"A":"一般名","B":"商品名","C":"略語","D":"[r]観察項目","E":"その他","F":"[b]催吐性","G":"[b]血管障害性","H":"[y]フィルター"},{"A":"Ｌ－アスパラギナーゼ","B":"ロイナーゼ","C":"L-ASP","F":"最小度","G":"ほぼなし"},{"A":"アクラルビシン","B":"アクラシノン","C":"ACR","D":"■アントラサイクリン系薬剤のアクラルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"軽度","G":"炎症性"},{"A":"アザシチジン","B":"ビダーザ","C":"AZA","F":"中等度","G":"ほぼなし"},{"A":"アテゾリズマブ","B":"テセントリク","D":"■アテゾリズマブ投与による有害事象は投与開始から１ヶ月までが頻度が高い。","E":"免疫チェックポイント阻害薬のひとつ。甲状腺機能不全、副腎機能不全、腸管障害などの有害事象がある。","F":"不明","G":"不明","H":"PVCフリー（フィルター付）"},{"A":"アムルビシン","B":"カルセド","C":"AMR","D":"■アムルビシン投与時、投与後、心電図異常の発現、また、類薬で重篤な心筋障害の発現が報告されているので、投与中は心電図モニタを装着する。\r\n■アントラサイクリン系薬剤のアムルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","E":"間質性肺炎又は肺線維症の患者はアムルビシン投与時、投与後の症状増悪に注意する。","F":"中等度","G":"壊死性"},{"A":"ナブパクリタキセル","B":"アブラキサン","C":"nab-PTX","D":"■ナブパクリタキセルには、アルブミンが含まれるため、治療開始時には輸血同意書を確認する。\r\n■ナブパクリタキセルの血管外漏出に注意する。","F":"軽度","G":"壊死性"},{"A":"イサツキシマブ","B":"サークリサ","F":"軽度","G":"ほぼなし","H":"PVCフリー（フィルター付）"},{"A":"イダルビシン","B":"イダマイシン","C":"IDR、IDA、IDAR","D":"■アントラサイクリン系薬剤のイダルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"中等度","G":"壊死性"},{"A":"イノツズマブ　オゾガマイシン","B":"ベスポンサ","C":"IO","F":"不明","G":"ほぼなし"},{"A":"イホスファミド","B":"イホマイド","C":"IFM","D":"■出血性膀胱炎、腎毒性、脳症、心毒性などがある。","E":"脳症は、軽度のうつやめまいなどで生じることもある。","F":"中等度","G":"炎症性"},{"A":"イリノテカン","B":"トポテシン","C":"CPT-11","D":"■イリノテカン投与時のコリン様症状（発汗・鼻汁・流涎・流涙・かすみ眼・腹痛・早発性下痢など）に注意する。","E":"投与時のコリン様症状を生じた場合には、虚血性心疾患、緑内障、前立腺肥大がないことを確認の上、ブチルスコポラミン臭化物20mg 1A + 生食 50mL を30分で点滴を考慮する。\r\nイリノテカンは、腸管麻痺、腸閉塞、間質性肺疾患又は肺線維症の患者への投与は禁忌。\r\n体質的に副作用の強く出る患者がいるため、UGT1A1を事前に検査することが推奨される。","F":"中等度","G":"炎症性"},{"A":"リポソーム化イリノテカン","B":"オニバイド","C":"nalIRI","D":"■イリノテカンリポソーム製剤投与時のコリン様症状（発汗・鼻汁・流涎・流涙・かすみ眼・腹痛・早発性下痢など）に注意する。","E":"腸管麻痺、腸閉塞、間質性肺疾患又は肺線維症の患者への投与は禁忌。","F":"中等度","G":"炎症性"},{"A":"エトポシド","B":"ラステット","C":"VP-16、ETP","F":"軽度","G":"炎症性","H":"PVCフリー（フィルター不要）"},{"A":"エノシタビン","B":"サンラビン","C":"BH-AC","F":"中等度","G":"ほぼなし","H":"PVCフリー（フィルター不要）"},{"A":"エピルビシン","B":"ファルモルビシン","C":"EPI","D":"■アントラサイクリン系薬剤のエピルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"中等度","G":"壊死性"},{"A":"エリブリン","B":"ハラヴェン","C":"ERI","F":"軽度","G":"ほぼなし"},{"A":"エロツズマブ","B":"エムプリシティ","F":"軽度","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"オキサリプラチン","B":"エルプラット","C":"L-OHP","D":"■オキサリプラチンには、早期・晩期の神経障害に留意する。\r\n■オキサリプラチン投与後のアレルギーは、30分以内、特に5サイクル以上に発現することが多いため観察を行う。","E":"アレルギーが生じた場合、速やかに中断し、投与時間を延長を考慮する。","F":"中等度","G":"炎症性"},{"A":"オビヌツズマブ","B":"ガザイバ","F":"最小度","G":"不明","H":"0.22μmフィルター"},{"A":"オファツムマブ","B":"アーゼラ","F":"中等度","G":"ほぼなし"},{"A":"カバジタキセル","B":"ジェブタナ","D":"■カバジタキセルの血管外漏出に注意する。","F":"軽度","G":"壊死性","H":"PVCフリー（フィルター付）"},{"A":"カルフィルゾミブ","B":"カイプロリス","F":"軽度","G":"炎症性"},{"A":"カルボプラチン","B":"パラプラチン","C":"CBDCA","D":"■カルボプラチンを反復投与することによって、重篤なアレルギー反応の頻度が増すことが知られているため観察を行う。アレルギー発現の中央値は８回目（範囲6~12回）である。","E":"カルボプラチンによるアレルギー反応は、初回や2-3回の治療で発症することはまれだが、それ以降現れることがある。","F":"中等度","G":"炎症性"},{"A":"クラドリビン","B":"ロイスタチン","C":"2-CdA","F":"最小度","G":"ほぼなし"},{"A":"クロファラビン","B":"エボルトラ","F":"中等度","G":"ほぼなし"},{"A":"ゲムシタビン","B":"ジェムザール","C":"GEM","D":"■ゲムシタビンの投与時間が60分以上になると、毒性が増強されるため、点滴時間に注意する。","E":"間質性肺疾患又は肺線維症の患者への投与は慎重に行う。","F":"軽度","G":"炎症性"},{"A":"ゲムツズマブ　オゾガマイシン","B":"マイロターグ","C":"GO","F":"最小度","G":"炎症性","H":"0.22μmフィルター"},{"A":"三酸化ヒ素","B":"トリセノックス","C":"ATO","F":"中等度","G":"不明"},{"A":"シクロホスファミド（≦1500mg/㎡）","B":"エンドキサン","C":"CPA、CPM","F":"中等度","G":"炎症性"},{"A":"シクロホスファミド（1500mg/㎡＜）","B":"エンドキサン","C":"CPA、CPM","F":"高度","G":"炎症性"},{"A":"シスプラチン","B":"シスプラチン、ブリプラチン","C":"CDDP","D":"■シスプラチンの投与時には腎機能障害を軽減するために補液が必要であり、体液貯留（体重）、尿量に注意する。\r\n■シスプラチン投与後の吃逆に対しては、メトクロプラミド投与を考慮する。","E":"シスプラチンの１回投与量が80mg/㎡以上で、総投与量が300mg/㎡（約6サイクル以上の投与）を超えると聴力低下・難聴，耳鳴の傾向が強くなる。","F":"高度","G":"炎症性"},{"A":"シタラビン（＜100mg/㎡）","B":"キロサイド","C":"Ara-C","F":"最小度","G":"ほぼなし"},{"A":"シタラビン（100～200mg/㎡）","B":"キロサイド","C":"Ara-C","F":"軽度","G":"ほぼなし"},{"A":"シタラビン（200mg/㎡＜）","B":"キロサイド","C":"Ara-C","F":"中等度","G":"ほぼなし"},{"A":"セツキシマブ","B":"アービタックス","C":"Cmab、CET","D":"■Infusion reactionが発現に注意する。赤肉（牛肉等）に対するアレルギー歴やマダニ咬傷歴のある患者では、症状が強くでることがあるため確認をする。","E":"セツキシマブに含まれるGalactose-α-1,3-galactose（α-gal）に対するIgE抗体を介した機序が報告されている。赤肉（牛肉等）に対するアレルギー歴やマダニ咬傷歴のある患者は、α-galに対するIgE抗体が検出されることが報告されている。\r\nざ瘡様皮疹が高頻度に生じる。","F":"最小度","G":"ほぼなし"},{"A":"ダウノルビシン","B":"ダウノマイシン","C":"DNR","D":"■アントラサイクリン系薬剤のダウノルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"中等度","G":"壊死性"},{"A":"ダカルバジン","B":"ダカルバジン","C":"DTIC","F":"高度","G":"炎症性"},{"A":"ダラツムマブ","B":"ダラザレックス","F":"不明","G":"不明","H":"PVCフリー（フィルター付）"},{"A":"テガフール","B":"フトラフール","C":"FT、TGF","F":"軽度","G":"ほぼなし"},{"A":"テムシロリムス","B":"トーリセル","F":"最小度","G":"ほぼなし","H":"PVCフリー（フィルター付）"},{"A":"デュルバルマブ","B":"イミフィンジ","F":"不明","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"ドキソルビシン","B":"アドリアシン、ドキシル","C":"DOX、DXR、ADR、ADM","D":"■アントラサイクリン系薬剤のドキソルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"中等度","G":"壊死性"},{"A":"ドセタキセル","B":"タキソテール","C":"DTX, DOC","D":"■ドセタキセル投与時の血管外漏出に注意する。","F":"軽度","G":"壊死性"},{"A":"トラスツズマブ","B":"ハーセプチン","C":"HER","D":"■トラスツズマブのインフュージョンリアクションに注意する。","F":"最小度","G":"ほぼなし"},{"A":"トラスツズマブ　エムタンシン","B":"カドサイラ","D":"■トラスツズマブ　エムタンシンのインフュージョンリアクションに注意する。","F":"軽度","G":"炎症性","H":"0.22μmフィルター"},{"A":"ニボルマブ","B":"オプジーボ","D":"■ニボルマブ投与による有害事象は投与開始から１ヶ月までが頻度が高い。","E":"免疫チェックポイント阻害薬のひとつ。甲状腺機能不全、副腎機能不全、腸管障害などの有害事象がある。","F":"最小度","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"ニムスチン","B":"ニドラン","C":"ACNU","F":"軽度","G":"ほぼなし"},{"A":"ネダプラチン","B":"アクプラ","C":"NDP、CDGP","F":"中等度","G":"炎症性"},{"A":"ノギテカン","B":"ハイカムチン","C":"NGT","F":"軽度","G":"ほぼなし"},{"A":"パクリタキセル","B":"タキソール","C":"PAC、PTX","D":"■パクリタキセルは粘稠度が高く、自然滴下の場合には、点滴時間を調整（目安1.7倍）することが必要。\r\n■パクリタキセルには、アルコールが含まれるため、投与前にアルコール過敏を確認する。\r\n■パクリタキセルは、アレルギーの発症頻度が高く、前投与薬（ファモチジン、ポララミン）が必要。\r\n■パクリタキセル投与中は心電図モニタする。\r\n■血管外漏出に注意する。","E":"アルコール過敏がある場合には、ナブパクリタキセル（アブラキサン）への変更を考慮する","F":"軽度","G":"壊死性"},{"A":"パニツムマブ","B":"ベクティビックス","C":"P-mab、Pmab","D":"■パニツムマブ投与時のインフュージョンリアクションが発現に注意する。","E":"ざ瘡様皮疹が高頻度に生じる。","F":"最小度","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"ビノレルビン","B":"ナベルビン","C":"VNR、NVB","D":"■血管外漏出に注意する。","F":"最小度","G":"壊死性"},{"A":"ピラルビシン","B":"テラルビシン","C":"THP","D":"■アントラサイクリン系薬剤のピラルビシンの血管外漏出の際には、デクスラゾキサン（サビーン®）の投与を考慮する。","F":"中等度","G":"壊死性"},{"A":"ビンクリスチン","B":"オンコビン","C":"VCR","D":"■血管外漏出に注意する。","F":"最小度","G":"壊死性"},{"A":"ビンデシン","B":"フィルデシン","C":"VDS","D":"■血管外漏出に注意する。","F":"最小度","G":"壊死性"},{"A":"ビンブラスチン","B":"エクザール","C":"VBL、VLB","D":"■血管外漏出に注意する。","F":"最小度","G":"壊死性"},{"A":"プララトレキサート","B":"ジフォルタ","C":"PDX","F":"軽度","G":"ほぼなし"},{"A":"フルオロウラシル","B":"5-FU","C":"FU","D":"■フルオロウラシルによる手足症候群について指導する。","E":"投与時間によって有害事象の発症率が異なる。","F":"軽度","G":"炎症性"},{"A":"フルダラビン","B":"フルダラ","C":"F-ara-A","F":"最小度","G":"ほぼなし"},{"A":"ブレオマイシン","B":"ブレオ","C":"BLM","D":"■肺障害を生じる可能性があるため、SpO2や症状に留意する。","E":"間質性肺疾患又は肺線維症の患者への投与は禁忌。","F":"最小度","G":"ほぼなし"},{"A":"ブレンツキシマブ ベドチン","B":"アドセトリス","F":"軽度","G":"ほぼなし"},{"A":"ベバシズマブ","B":"アバスチン","C":"BV、BEV","D":"■ベバシズマブのインフュージョンリアクションに注意する。\r\n■ベバシズマブの初回投与は90分、２回目は60分、３回目以降は30分に短縮することができる。\r\n■ベバシズマブの使用により、徐々に高血圧を悪化させることがあるため、血圧コントロールに注意する。\r\n■ベバシズマブのは腎障害をもたらすことがあるため、定期的に尿蛋白（尿蛋白量）を確認する。","E":"出血傾向を生じる。\r\n分子抗体薬（血管新生阻害薬）のひとつ。","F":"最小度","G":"ほぼなし"},{"A":"ペプロマイシン","B":"ペプレオ","C":"PEP","F":"最小度","G":"ほぼなし"},{"A":"ペムブロリズマブ","B":"キイトルーダ","C":"PEMBRO","D":"■ペムブロリズマブ投与による有害事象は投与開始から１ヶ月までが頻度が高い。","E":"免疫チェックポイント阻害薬のひとつ。甲状腺機能不全、副腎機能不全、腸管障害などの有害事象がある。","F":"最小度","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"ペメトレキセド","B":"アリムタ","C":"PEM","D":"■ペメトレキセドの有害事象を軽減するため、初回投与の7日以上前から葉酸として1日1回0.5mgを連日経口投与する。なお、本剤の投与を中止又は終了する場合には、本剤最終投与日から22日目まで可能な限り葉酸を投与されていることを確認する。\r\n■ペメトレキセドの有害事象を軽減するため、初回投与の少なくとも7日前に、ビタミンB12として1回1mgを筋肉内投与する。その後、本剤投与期間中及び投与中止後22日目まで9週ごと（3コースごと）に1回投与されていることを確認する。","F":"軽度","G":"ほぼなし"},{"A":"ペルツズマブ","B":"パージェタ","C":"PER","F":"最小度","G":"ほぼなし"},{"A":"ベンダムスチン","B":"トレアキシン","C":"Benda","F":"中等度","G":"炎症性"},{"A":"ボルテゾミブ","B":"ベルケイド","C":"BOR、VEL","F":"最小度","G":"炎症性"},{"A":"マイトマイシンＣ","B":"マイトマイシン","C":"MMC","D":"■血管外漏出に注意する。","F":"軽度","G":"壊死性"},{"A":"ミトキサントロン","B":"ノバントロン","C":"MIT","D":"■血管外漏出に注意する。","F":"軽度","G":"壊死性"},{"A":"ミリプラチン","B":"ミリプラ","F":"中等度","G":"不明"},{"A":"メトトレキサート（≦50mg/㎡）","B":"メソトレキセート","C":"MTX","F":"最小度","G":"ほぼなし"},{"A":"メトトレキサート（250～1000mg/m）","B":"メソトレキセート","C":"MTX","F":"中等度","G":"ほぼなし"},{"A":"メトトレキサート（50～250mg/㎡）","B":"メソトレキセート","C":"MTX","F":"軽度","G":"ほぼなし"},{"A":"メルファラン","B":"アルケラン","C":"L-PAM","F":"中等度","G":"炎症性"},{"A":"ラニムスチン","B":"サイメリン","C":"MCNU","F":"軽度","G":"炎症性"},{"A":"ラムシルマブ","B":"サイラムザ","C":"RAM, Ram","D":"■ラムシルマブのインフュージョンリアクションに注意する。\r\n■ラムシルマブの初回投与は60分、２回目以降は30分に短縮することができる。\r\n■ラムシルマブの使用により、徐々に高血圧を悪化させることがあるため、血圧コントロールに注意する。\r\n■ラムシルマブの使用により、腎障害をもたらすことがあるため、定期的に尿蛋白（尿蛋白量）を確認する。","E":"出血傾向を生じる。\r\n分子抗体薬（血管新生阻害薬）のひとつ。","F":"中等度","G":"ほぼなし","H":"0.22μmフィルター"},{"A":"リツキシマブ","B":"リツキサン","C":"RIT","D":"■リツキシマブのインフュージョンリアクションに注意する。","F":"最小度","G":"ほぼなし"},{"A":"ロミデプシン","B":"イストダックス","F":"軽度","G":"ほぼなし"},{"A":"レボホリナート","B":"レボホリナート","C":"LV、I-LV","E":"フルオロウラシルによるDNA合成阻害作用を増強することで、フルオロウラシルの抗腫瘍効果を高める薬","F":"最小度","G":"ほぼなし","H":"不要"},{"A":"カペシタビン","B":"カペシタビン、ゼローダ","C":"Cape","D":"■カペシタビンによる手足症候群について指導する。","E":"下痢を生じることがある。","F":"軽度","G":"なし"},{"A":"S-1","B":"ティーエスワン、TS-1","C":"S-1","D":"■S-1による手足症候群について指導する。","E":"流涙を生じる頻度が高い","F":"軽度","G":"なし"}];